CD47 and cancer: Since our results and a previous study indicate that this pathway is activated in triple-negative breast cancer28,29, further experiments are necessary to determine the benefit of targeting CD47 in specific cancer subtypes that may respond differently to genotoxic treatments, depending on the level of TSP1 and of senescence induction.